Lantero-Rodriguez, Juan http://orcid.org/0000-0002-7426-678X
Montoliu-Gaya, Laia
Benedet, Andrea L.
Vrillon, Agathe
Dumurgier, Julien
Cognat, Emmanuel
Brum, Wagner S.
Rahmouni, Nesrine
Stevenson, Jenna
Servaes, Stijn
Therriault, Joseph
Becker, Bruno
Brinkmalm, Gunnar
Snellman, Anniina
Huber, Hanna
Kvartsberg, Hlin
Ashton, Nicholas J.
Zetterberg, Henrik
Paquet, Claire
Rosa-Neto, Pedro
Blennow, Kaj
Article History
Received: 16 August 2023
Revised: 31 October 2023
Accepted: 16 November 2023
First Online: 6 January 2024
Declarations
:
: KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). JLR, LMG, ALB, AV, JD, EC, WSB, NR, JS, SS, JT, BB, GB, AS, HH, HK, NJA, CP and PRN report no conflicts of interest.